SCHEMBL5769249

SCHEMBL5769249

CN(C(=O)OC(C)(C)C)c1cccc(S(=O)(=O)N(C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)Oc2ccoc2)CC(C)(C)CCCC#N)c1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SPPL2A Q8TCT8 1/20 0.37
PSEN1 P49768 2/20 0.35
PSEN2 P49810 2/20 0.35
APH1B Q8WW43 2/20 0.35
NCSTN Q92542 2/20 0.35
APH1A Q96BI3 2/20 0.35
PSENEN Q9NZ42 2/20 0.35
KLK5 Q9Y337 1/20 0.34
MLNR O43193 1/20 0.34
ABCB11 O95342 1/20 0.34
LMNA P02545 1/20 0.34
CTSD P07339 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP3A5 P20815 1/20 0.34
CNR1 P21554 1/20 0.34
TBXAS1 P24557 1/20 0.34
ADRA1A P35348 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7397547 0.87 SPPL2A (0.37) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL5770037 0.86 SPPL2A (0.40) SPPL2AMLNRABCB11LMNACTSD
SCHEMBL5774287 0.85 SPPL2A (0.36) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL1601896 0.82 ABCB1 (0.56) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL1601893 0.82 ABCB1 (0.56) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL12709310 0.81 SPPL2A (0.44) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL7396185 0.81 SPPL2A (0.43) SPPL2AMLNRABCB11LMNACTSD
SCHEMBL12709389 0.80 KLK5 (0.43) SPPL2APSEN1PSEN2APH1BNCSTN
SCHEMBL5767519 0.80 SPPL2A (0.40) SPPL2AMLNRABCB11LMNACTSD
SCHEMBL1602262 0.79 ABCB1 (0.56) MLNRABCB11LMNACTSDCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637518-A2 Inhibitors of aspartyl protease Vertex Pharmaceuticals Incorporated (US) 2006-03-22 EP disclosed